International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

placeholder

Clinical Toxicology/Drugs of Misuse Committee

Last Updated: Wednesday, 27 July 2022 21:45
Peter Zweipfenning   Eric Franssen   Contact Us

Vice-Chair

  

Chair

  

Contact Us
Peter Zweipfenning
MVZ Labor Stein, Germany		   Eric Franssen
Utrecht, Netherlands		   Scientific Committee
Clinical Toxicology/DOM Committee

 

Committee Purpose

  • To educate a new generation of toxicologists
  • To provide evidence-based recommendations for CTDOA scientists, clinicians, laboratory and health care personal about drugs of use and misuse and their interactions.
  • To promote the knowledge and understanding of drug analysis, clinical toxicological normal and abnormal values and interpretation of results.
  • To develop communication between scientists and physicians of all disciplines involved in Clinical Toxicology of therapeutics and drugs of misuse.
  • To enhance the collaboration between all the toxicologists belonging to the committee and the members of other committees.
  • To encourage the effective application of CT in all aspects of medicine, with the aim of optimizing clinical therapeutic use, avoid drug adverse reactions or interaction between drugs of use and misuse and maximizing the clinical and economic benefits.
  • To focus on Pharmacogenetics — Immuno-pharmaco-genetics — Personalized medicine.

Activities Planned/Committee Initiatives Currently in Progress

  • 8 Committee members on Planning Committee of 2020 Congress
  • Kamisha Johnson Davis is the Chair of the Communication Committee IATDMCT
  • Alain Verstraete is a member of the Communication Committee IATDMCT
  • Manuela Neuman is a co-editor of e-news.

Publications, Scientific Contributions

Publications in Therapeutic Drug Monitoring

Smits TA, Gresnigt FMJ, van Groen BD, Franssen EJF, et al. Prospective Investigation of the Performance of 2 Gamma-Hydroxybutyric Acid Tests: DrugCheck GHB Single Test and Viva-E GHB Immunoassay. Ther Drug Monit. 2020 Feb;42(1):139-145. doi: 10.1097/FTD.0000000000000677.

Märtson A-G, Touw D, et al. Ganciclovir Therapeutic Drug Monitoring: A Case Series. Therapeutic Drug Monitoring. 2019 Apr 1;41(2):107-110. https://doi.org/10.1097/FTD.0000000000000598.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Touw DJ, et al. Darunavir population pharmacokinetic model based on HIV outpatient data. Therapeutic Drug Monitoring. 2019;41(1):59-65. https://doi.org/10.1097/FTD.0000000000000576.

Colman S, Stove V, De Waele JJ, Verstraete AG. Measuring Unbound Versus Total Piperacillin Concentrations in Plasma of Critically Ill Patients: Methodological Issues and Relevance. Ther Drug Monit. 2019;41(3):325-330. doi: 10.1097/FTD.0000000000000602.

Neuman MG. Biomarkers of Drug-Induced Liver Toxicity.Therapeutic Drug Monitoring. 2019 - Volume 41 - 2 - p 227–234 doi: 10.1097/FTD.0000000000000610.

Contrucci RR, Brunt TM, Inan F, Franssen EJF, Hondebrink L Synthetic Cathinones and Their Potential Interactions with Prescription Drugs. Ther Drug Monit. 2020 Feb;42(1):75-82. doi: 10.1097/FTD.0000000000000682.

Smy L, Sadler AJ, McMillin GA. Evaluation of imatinib concentrations in samples submitted for BCR-ABL1 or imatinib testing - evidence to support therapeutic drug monitoring for dose optimization? Ther Drug Monit. 2020 May 6. Online ahead of print.

Neuman MG. Biomarkers of Drug-Induced Liver Toxicity. Therapeutic Drug Monitoring. 2019 - Volume 41 - Issue 2 - p 227–234 doi: 10.1097/FTD.0000000000000610.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Touw DJ, Alffenaar JW. Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes. Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10/1097 (IF2018 2.047).

Oude Munnink TH, van der Meer A, de Haan JJ, Touw DJ, van Kruchten M. Grand Round: Reversible impaired methotrexate clearance after platinum-based chemotherapy for osteosarcoma. Therapeutic Drug Monitoring. 2019 https://doi.org/10.1097/FTD.0000000000000662.

Zuur MA, Veenhof H, Aleksa A, Boveneind-Vrubleuskaya NV, Darmawan E, Hasnain MG et al Touw DJ,. Quality Assessment of Dried Blood Spots from Tuberculosis Patients from Four Countries. Therapeutic Drug Monitoring. 2019 June 4, https://doi.org/10.1097/FTD.0000000000000659.

Capiau S, Veenhof H, Koster R, Bergqvist Y, Boettcher M, Halmingh O et al Touw DJ,. Official International Association for Therapeutic Drug Monitoring and Toxicology guideline: Development and Validation of Dried Blood Spot-based Methods for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring. 2019 Aug;41:409-430. https://doi.org/10.1097/FTD.0000000000000643.

Publication in Compass: 2019-2020

Is Gabapentin (Neurontin) Misuse on your radar? Kamisha L. Johnson-Davis. University of Utah,Utah, USA

Alcohol, Nutrition, Microbiota and Liver Damage. Manuela G. Neuman. In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, Canada

The Poisoned Patient: How to Communicate with Clinicians and Guide Further Testing- Amitava Desgupta, University of Huston, Texas, USA

Clinical Toxicology Assessment in Alcohol and Drug-induced Liver Injury in Haemochromatosis. Manuela G. Neuman, In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, Canada